CoChat

Prevalence of KRAS mutations in metastatic colorectal cancer: A retrospective observational study from India

Veldore, VH, Rao, MR, Prabhudesai, SA, Tejaswi, R, Kakara, S, Pattanayak, S, Krishnamoorthy, N, Tejaswini, BN, Hazarika, D, Gangoli, A, Rahman, SM, Dixit, J, Naik, R, Diwakar, RB, Satheesh, CT, Shashidhara, HP, Patil, S, Gopinath, KS, Kumar, BS · 2014 · Indian Journal of Cancer
Cited by 9

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4103/0019-509x.175371

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 46

  1. Ferlay, 2015, Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012, Int J Cancer, E359
  2. Sung, 2005, Increasing incidence of colorectal cancer in Asia: Implications for screening, Lancet Oncol, 871
  3. Jemal, 2011, Global cancer statistics, CA Cancer J Clin, 69
  4. Mateka, 2013, Interesting trends in incidence and mortality rates of colorectal cancer in the United States of America, J Gastrointest Dig Syst, 004
  5. Fearon, 1990, A genetic model for colorectal tumorigenesis, Cell, 759
  6. Ciardiello, 2003, Epidermal growth factor receptor (EGFR) as a target in cancer therapy: Understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs, Eur J Cancer, 1348
  7. Shields, 2000, Understanding Ras: 'It ain't over 'til it's over', Trends Cell Biol, 147
  8. Traxler, 2001, Tyrosine kinase inhibitors: From rational design to clinical trials, Med Res Rev, 499
  9. Lièvre, 2006, KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer, Cancer Res, 3992
  10. Amado, 2008, Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer, J Clin Oncol, 1626
  11. Punt CJ, Tol J, Rodenburg CJ, Cats A, Creemers G, SchramaJG. et al. Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). In: Program and abstracts of the 44rd American Society of Clinical Oncology Annual Meeting; May 30-June 3, 2008; Chicago, IL. Abstract LBA4011. · DOI · Paper page
  12. Hecht JR, Mitchell E, Chidiac T, Carroll Scroggin, Christopher Hagenstad, David Spigel, et al. An updated analysis of safety and efficacy of oxaliplatin (Ox)/bevacizumab (bev) +/-panitumumab (pmab) for first-line treatment (tx) of metastatic colorectal cancer (mCRC) from a randomized controlled trial (PACCE). In: Program and abstracts of the 2008 Gastrointestinal Cancers Symposium; January 25-27, 2008; Orlando, FL. Abstract 273.
  13. Jimeno, 2009, KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: Practical application of patient selection, J Clin Oncol, 1130
  14. Bos, 1989, Ras oncogenes in human cancer: A review, Cancer Res, 4682
  15. De, 2008, KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.Ann Oncol, 508
  16. Kressner, 1998, Ki-ras mutations and prognosis in colorectal cancer, Eur J Cancer, 518
  17. Riely, 2008, KRAS mutations: An old oncogene becomes a new predictive biomarker, J Mol Diagn, 493
  18. Breivik, 1994, K-ras mutation in colorectal cancer: Relations to patient age, sex and tumour location, Br J Cancer, 367
  19. Shen, 2011, Clinical significance of K-ras and BRAF mutations in Chinese colorectal cancer patients, World J Gastroenterol, 809
  20. Sammoud, 2012, Relationship between expression of ras p21 oncoprotein and mutation status of the K-ras gene in sporadic colorectal cancer patients in Tunisia, Appl Immunohistochem Mol Morphol, 146
  21. Wu, 2005, Frequency and spectrum of K-RAS codons 12 and 13 mutations in colorectal adenocarcinomas from Taiwan, Cancer Genet Cytogenet, 55
  22. Okulczyk, 2003, Evaluation of K-RAS gene in colorectal cancer, Folia Histochem Cytobiol, 97
  23. Breivik, 1997, Different genetic pathways to proximal and distal colorectal cancer influenced by sex-related factors, Int J Cancer, 664
  24. Phang, 1995, K-ras mutation in colorectal carcinomas from singapore, Int J Oncol, 191
  25. Sorich, 2015, Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: A meta-analysis of randomized, controlled trials, Ann Oncol, 13
  26. Stein, 2014, How to select the optimal treatment for first line metastatic colorectal cancer, World J Gastroenterol, 899
  27. Slattery, 2000, Associations between dietary intake and Ki-ras mutations in colon tumors: A population-based study, Cancer Res, 6935
  28. (A) Ries L AG, Melbert D, Krapcho M, et al. SEER cancer statistics review, 1975–2005. Bethesda, MD: 2008. (B) Jemal A, Clegg LX, Ward E, Ries LA, Wu X, Jamison PM, Wingo PA, Howe HL, Anderson RN, Edwards BK. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer. 2004 1;101 (1):3-27. (C) http://seer.cancer.gov/statfacts/html/colorect.html. · DOI · Paper page
  29. Angulo, 2010, A commercial real-time PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: A morphology-based approach in colorectal carcinoma, J Mol Diagn, 292
  30. Whitehall, 2009, A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting, J Mol Diagn, 543
  31. Sahoo, 2011, Screening for EGFR mutations in lung cancer, a report from India, Lung Cancer, 316
  32. Al-Allawi, 2012, The frequency and spectrum of K-ras mutations among Iraqi patients with sporadic colorectal carcinoma, Indian J Cancer, 163
  33. Samowitz, 2000, Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: A population-based study, Cancer Epidemiol Biomarkers Prev, 1193
  34. Elnatan, 1996, C-KI-RAS activation and the biological behaviour of proximal and distal colonic adenocarcinomas, Eur J Cancer, 491
  35. Einspahr, 2006, Associations of Ki-ras proto-oncogene mutation and p53 gene overexpression in sporadic colorectal adenomas with demographic and clinicopathologic characteristics, Cancer Epidemiol Biomarkers Prev, 1443
  36. Baskin Y, Dagdeviren YK, Calibasi G, Canda AE, Sarioglu S, Ellidokuz H, Oztop I. KRAS mutation profile differences between rectosigmoid localized adenocarcinomas and colon adenocarcinomas. J Gastrointest Oncol. 2014 Aug;5(4):265-9
  37. Parkin DM, Whelan SL, Ferlay L, Young RJ. Cancer Incidence in Five Continents (IARC Sci. Publ. No. 143) Series. Vol. 143. Lyon: International Agency for Research on Cancer; 1997. p. 566-7.
  38. Scott, 2014, KRAS mutation testing of metastatic colorectal cancer in Australia: Where are we at?, Asia Pac J Clin Oncol, 261
  39. Nakanishi, 2013, Prognostic relevance of KRAS and BRAF mutations in Japanese patients with colorectal cancer, Int J Clin Oncol, 1042
  40. Phipps, 2013, KRAS-mutation status in relation to colorectal cancer survival: The joint impact of correlated tumour markers, Br J Cancer, 1757
  41. Díaz-Rubio, 2012, Role of Kras status in patients with metastatic colorectal cancer receiving first-line chemotherapy plus bevacizumab: A TTD group cooperative study, PLoS One, e47345
  42. Brink, 2003, K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study, Carcinogenesis, 703
  43. Zhu, 2012, KRAS and BRAF gene mutations in correlation with clinicopathologic features of colorectal carcinoma in Chinese, Zhonghua Bing Li Xue Za Zhi, 584
  44. Bisht, 2014, Molecular spectrum of KRAS, BRAF, and PIK3CA gene mutation: Determination of frequency, distribution pattern in Indian colorectal carcinoma, Med Oncol, 124
  45. Sameer, 2009, Mutation pattern of K-ras gene in colorectal cancer patients of Kashmir: A report, Indian J Cancer, 219
  46. Sinha, 2013, Kras gene mutation and RASSF1A, FHIT and MGMT gene promoter hypermethylation: Indicators of tumor staging and metastasis in adenocarcinomatous sporadic colorectal cancer in Indian population, PLoS One, e60142

Cited by

See all 9

Metadata

Authors
Veldore, V., Rao, M., Prabhudesai, S., Tejaswi, R., Kakara, S., Pattanayak, S., Krishnamoorthy, N., Tejaswini, B., Hazarika, D., Gangoli, A., Rahman, S., Dixit, J., Naik, R., Diwakar, R., Satheesh, C., Shashidhara, H., Patil, S., Gopinath, K., & Kumar, B.
Venue
Indian Journal of Cancer
Published
2014
Volume
51
Issue
4
Pages
531
ISSN
0019-509X
Cited by
9
References
6
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prevalence of KRAS mutations in metastatic colorectal cancer: A retrospective observational study from India. https://app.cochat.ai/papers/10.4103/0019-509x.175371
The paper
Veldore, V., Rao, M., Prabhudesai, S., Tejaswi, R., Kakara, S., Pattanayak, S., Krishnamoorthy, N., Tejaswini, B., Hazarika, D., Gangoli, A., Rahman, S., Dixit, J., Naik, R., Diwakar, R., Satheesh, C., Shashidhara, H., Patil, S., Gopinath, K., & Kumar, B. (2014). Prevalence of KRAS mutations in metastatic colorectal cancer: A retrospective observational study from India. Indian Journal of Cancer. https://doi.org/10.4103/0019-509x.175371

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.